Future Of Cardio And Mental Health Will Be Defined By Digital Advances

Cardiovascular diseases are responsible for 30% of worldwide deaths, and about 25% of the global population experiences mental illness each year. The negative impact of these conditions on society remain substantial. Development of digital tools to provide support to high-risk groups and patients, healthcare providers, and communities in general, is an area of significant opportunity.

IV1812_Body Analysis_657922240 _1200.jpg
Exploring digital innovation in heart and mental health • Source: Shutterstock

Health care for a long time has relied on the traditional treatment-based, physician-centric approach, which is strained by increasing demand and resource constraints. This applies to many chronic diseases including cardiovascular diseases and mental illnesses. However, these approaches are no longer enough to tackle the long-term health crisis and there is dire need for effective preventive strategies and long-term, cost-effective, sustainable solutions. Digital health tools are one such solution, which is cost-effective and has a capacity to reach a great number of patients and affect them.

There is strong evidence that digital health technology adopting behavioral interventions can significantly reduce the burden of many chronic conditions....

More from Market Intelligence

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By 

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.